Controlled and Selective Photo-oxidation of Amyloid-β Fibrils by Oligomeric -Phenylene Ethynylenes
Overview
Biotechnology
Authors
Affiliations
Photodynamic therapy (PDT) has been explored as a therapeutic strategy to clear toxic amyloid aggregates involved in neurodegenerative disorders such as Alzheimer's disease. A major limitation of PDT is off-target oxidation, which can be lethal for the surrounding cells. We have shown that a novel class of oligo--phenylene ethynylenes (OPEs) exhibit selective binding and fluorescence turn-on in the presence of prefibrillar and fibrillar aggregates of disease-relevant proteins such as amyloid-β (Aβ) and α-synuclein. Concomitant with fluorescence turn-on, OPE also photosensitizes singlet oxygen under illumination through the generation of a triplet state, pointing to the potential application of OPEs as photosensitizers in PDT. Herein, we investigated the photosensitizing activity of an anionic OPE for the photo-oxidation of Aβ fibrils and compared its efficacy to the well-known but nonselective photosensitizer methylene blue (MB). Our results show that, while MB photo-oxidized both monomeric and fibrillar conformers of Aβ40, OPE oxidized only Aβ40 fibrils, targeting two histidine residues on the fibril surface and a methionine residue located in the fibril core. Oxidized fibrils were shorter and more dispersed but retained the characteristic β-sheet rich fibrillar structure and the ability to seed further fibril growth. Importantly, the oxidized fibrils displayed low toxicity. We have thus discovered a class of novel theranostics for the simultaneous detection and oxidization of amyloid aggregates. Importantly, the selectivity of OPE's photosensitizing activity overcomes the limitation of off-target oxidation of traditional photosensitizers and represents an advancement of PDT as a viable strategy to treat neurodegenerative disorders.
Noninvasive Treatment of Alzheimer's Disease with Scintillating Nanotubes.
Senapati S, Secchi V, Cova F, Richman M, Villa I, Yehuda R Adv Healthc Mater. 2023; 12(32):e2301527.
PMID: 37826854 PMC: 11469333. DOI: 10.1002/adhm.202301527.
Maghsoodi F, Martin T, Chi E ACS Omega. 2023; 8(11):10148-10159.
PMID: 36969430 PMC: 10035002. DOI: 10.1021/acsomega.2c07468.
Monge F, Fanni A, Donabedian P, Hulse J, Maphis N, Jiang S Biosensors (Basel). 2023; 13(2).
PMID: 36831917 PMC: 9953543. DOI: 10.3390/bios13020151.
Li H, Tan Y, Cheng X, Zhang Z, Huang J, Hui S Front Pharmacol. 2022; 13:990307.
PMID: 36339577 PMC: 9630565. DOI: 10.3389/fphar.2022.990307.